Drugs / REGN6569
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04465487 | Oct 2020 → Feb 2025 | head and neck squamous cell carcinoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN6569 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04465487 ↗ |
| Modality | Monoclonal antibody | “an Anti-GITR mAb” NCT04465487 ↗ |
| Route | Intravenous | “Administered by intravenous (IV) infusion” NCT04465487 ↗ |
| Target | GITR | “an Anti-GITR mAb” NCT04465487 ↗ |